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Scandinavia is considered a region with a low prevalence of antimicrobial resistance. However, the number
of multidrug-resistant (MDR) Gram-negative bacteria is increasing, including metallo--lactamase (MBL)-
producing Pseudomonas aeruginosa. In this study MBL-producing P. aeruginosa isolates identified in Norway
(n  4) and Sweden (n  9) from 1999 to 2007 were characterized. Two international clonal complexes (CC),
CC111 (n 8) and CC235 (n 2), previously associated with MBL-producing isolates, were dominant. CC111
isolates (ST111/229; serotype O12; blaVIM-2) included clonally related isolates identified in Skåne County,
Sweden (n 6), and two isolates associated with importation from Greece and Denmark. In all CC111 isolates,
blaVIM-2 was located in integron In59.2 or In59 variants. The two CC235 isolates (ST235/ST230; serotype O11;
blaVIM-4) were imported from Greece and Cyprus, were possibly clonally related, and carried blaVIM-4 in two
different integron structures. Three isolates imported from Ghana (ST233; serotype O6; blaVIM-2), Tunisia
(ST654; serotype O11; blaVIM-2), and Thailand (ST260; serotype O6; blaIMP-14) were clonally unrelated. ST233
was part of a new CC (CC233) that included other MBL-producing isolates, while ST654 could also be part of
a new CC associated with MBL producers. In the isolates imported from Ghana and Tunisia, blaVIM-2 was part
of unusual integron structures lacking the 3 conserved segment and associated with transposons. The blaVIM
gene was found to be located on the chromosome in all isolates. Known risk factors for acquisition of MBL were
reported for all patients except one. The findings suggest that both import of successful international clones
and local clonal expansion contribute to the emergence of MBL-producing P. aeruginosa in Scandinavia.
Metallo--lactamases (MBLs) comprise one of the most
clinically important families of -lactamases in Gram-negative
bacilli (30, 43), largely due to their association with mobile
genetic elements that often carry other resistance genes,
resulting in multidrug resistance (MDR) (30, 43). Moreover, the
hydrolytic spectrum of MBLs includes all -lactams with the
exception of monobactams, and they are not inhibited by clas-
sical serine -lactamase inhibitors (30, 43). The acquired
MBLs include the VIM and IMP families (30, 43), SPM-1 (30,
43), GIM-1 (2), SIM-1 (17), AIM-1 (44), KHM-1 (36), NDM-1
(45), and DIM-1 (29). In particular, VIM-2 has emerged as a
dominant MBL variant worldwide. Multilocus sequence typing
(MLST) has identified international clonal complexes (CCs)
responsible for the dissemination of MBL-producing Pseudo-
monas aeruginosa, particularly in European countries (7, 8, 12,
18, 20, 33), but also in Japan (15), Singapore, and Brazil (http:
//pubmlst.org/paeruginosa/).
Infections with MBL-producing P. aeruginosa isolates have
been shown to be associated with higher mortality rates than
infections with MBL-negative P. aeruginosa isolates (16, 46, 48)
and a higher incidence of invasive disease (16). Risk factors
associated with infections by MBL-producing P. aeruginosa
isolates include recent use of -lactams or fluoroquinolones,
renal failure, indwelling urinary catheters, neurological dis-
ease, antineoplastic chemotherapy, corticosteroid therapy,
and/or intensive care unit stay (14, 47).
The majority of the observed carbapenem resistance in Nor-
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way and Sweden is due to the overexpression of efflux pumps
and decreased permeability and not to carbapenemases (11,
31). The emergence of new mobile resistance mechanisms of-
ten originates from an exogenous source, exemplified by the
first two MBL-producing isolates identified in Norway and
Sweden, which were both associated with hospitalization
abroad (13, 32).
In this study, we examined the molecular epidemiology of
MBL-producing P. aeruginosa isolates identified in Norway
and Sweden from 1999 to 2007, along with the genetic context
of the blaMBL genes.
(Part of this study was presented at the 18th European Con-
gress of Clinical Microbiology and Infectious Disease [ECCMID],
Barcelona, Spain.)
MATERIALS AND METHODS
Bacterial isolates. The clinical isolates investigated in this study are listed in
Table 1. Submissions were based on resistance to carbapenems, ceftazidime,
and/or piperacillin-tazobactam as stated in the national guidelines (http://www
.unn.no/afa/category10274.html and http://www.srga.org/RAFMETOD/betamas
.htm). Bacterial identification was performed using Vitek 2 (bioMe´rieux, Marcy
l’Etoile, France). P. aeruginosa RON-2, harboring blaVIM-2 as part of integron 59
(In59) (28), was used for comparison in pulsed-field gel electrophoresis (PFGE)
and MLST. Rifampin-resistant P. aeruginosa PAO1 and Escherichia coli J53-2
were used in transfer experiments. P. aeruginosa 303-03 and R22 carrying
blaVIM-4 and blaVIM-2 on an 400-kb (26) and an 100-kb plasmid (unpublished
results), respectively, were used as controls in plasmid analysis. P. aeruginosa
170-01 was used as a template for preparation of the blaVIM-probe (26).
Identification of MBL-producing isolates. The presence of MBLs was inves-
tigated using the MBL Etest (AB bioMe´rieux, Solna, Sweden) and by qualitative
spectrophotometric analysis of crude cell extracts for imipenem hydrolysis and
subsequent inhibition with EDTA as previously described (41). Identification of
the MBL-encoding genes was done using multiplex real-time PCR as described
by Mendes et al. (22).
Susceptibility testing. MICs were determined with Etest (AB bioMe´rieux)
according to the manufacturer’s instructions and interpreted with clinical break-
points from the European Committee for Antimicrobial Susceptibility Testing
(EUCAST) (http://www.eucast.org/clinical_breakpoints/).
Serotyping. All isolates were serotyped using monoclonal O-antigen sera (Bio-
Rad, Marnes-La-Coquette, France) as described in the manufacturer’s instruc-
tions.
PFGE. PFGE was performed on genomic DNA digested with SpeI (New
England Biolabs, Hirts, United Kingdom) in agarose plugs at 37°C until com-
pletion, and DNA fragments were separated as previously described (12). Den-
drograms were generated by the unweighted-pair group method using average
linkages (UPGMA) with the band position tolerance set to 1.0%. A cutoff value
of an 80% level of similarity, corresponding to a maximum six-band difference,
was used to determine the genetic relatedness among isolates (12).
MLST. MLST was performed according to the method of Curran et al. (4),
and the resulting PCR products were sequenced using BigDye 3.1 terminator
chemistry on an ABI Prism 3100 Genetic Analyzer (Applied Biosystems, Foster
City, CA). Experimentally determined nucleotide sequences were compared to
existing alleles in the MLST database (http://pubmlst.org/paeruginosa/) and as-
signed allelic numbers, and sequence types (STs) were obtained. Isolates having
five or more identical alleles were considered part of the same clonal complex
(10). The BURST algorithm was used to analyze the MLST findings.
Determination of MBL genes and their adjacent genetic structures. The MBL
gene, the surrounding genetic structure, and its linkage to integrons and Tn21-
like transposons were analyzed by PCR and sequenced using previously de-
scribed primers and custom-designed primers (Table 2). Sequence analysis was
performed using SeqManII software (DNAStar, Madison, WI) and compared
with sequences deposited in the GenBank database (http://www.ncbi.nlm.nih
.gov).
Genomic localization of blaVIM. The genetic localization of blaVIM genes was
examined with S1 nuclease-treated total DNA separated by PFGE, followed by
in-gel hybridization using a blaVIM probe as previously described (26).
Transfer of resistance. Conjugal-transfer experiments were carried out by
filter mating with a donor/recipient ratio of 1:1 at 37°C. Rifampin-resistant E. coli
J53-2 and P. aeruginosa PAO1 were used as recipient strains. Transconjugants
were selected on Luria-Bertani (LB) agar plates (Becton Dickinson, Sparks,
MD) supplemented with 150 g/ml rifampin (Sigma-Aldrich, St. Louis, MO) and
4 g/ml ceftazidime (Sigma-Aldrich).
Nucleotide sequence accession numbers. The nucleotide sequences obtained
in this study have been deposited in GenBank with accession numbers
FN397623, FN397626, FN397624, FN397625, FN397622, FN397621, FN397620,
FN397619, FN397618, FN397628, and FN397627.
RESULTS
Origin of isolates. In Norway, all four MBL-positive isolates
identified were linked to import from Ghana (32), Cyprus,
Thailand, and Denmark (Table 1). In Sweden, three isolates
were imported (Greece [n  2] and Tunisia). However, six
isolates were shown to be endogenous to Skåne County
(Malmo¨/Lund), Sweden, from patients with no history of re-
cent international travel. The first two of these isolates (U9-
19005 and B4-25753) were identified at Malmo¨ University
Hospital in 1999 and 2004, while four isolates were identified
at Lund University Hospital in 2007. Several of the patients
TABLE 1. Clinical data, MBL allele, serotype, PFGE-type, and MLST results for MBL-producing P. aeruginosa isolates from
Norway and Sweden
Isolate Yr ofisolation Specimen Risk factor(s)
a Place of isolationb Hospitalizationabroad,c place
MBL
allele Serotype ST
Clonal
complex
PFGE
type
U9-19005 1999 Urine Renal failure Malmo¨, SWE N VIM-2 O12 111 111 A1
PA66d 2001 Urine ICU, ND Stockholm, SWE Y, Greece VIM-4 O11 230 235 D
AK-5493d 2004 Eye secretion ICU, ND Stockholm, SWE Y, Greece VIM-2 O12 229 111 C
B4-25753 2004 Blood ICU Malmo¨, SWE N VIM-2 O12 111 111 A1
K34-7d 2006 Tracheal secretion ICU Oslo, NOR Y, Ghana VIM-2 O6 233 233 F
K34-73 2006 Tracheal secretion ICU Akershus, NOR Y, Cyprus VIM-4 O11 235 235 D1
BU-20287 2007 Urine Urinary catheter Lund, SWE N VIM-2 O12 111 111 A2
BU-43038 2007 Urine Urinary catheter Lund, SWE N VIM-2 O12 111 111 A2
BU-36178 2007 Urine Urinary catheter Lund, SWE N VIM-2 O12 111 111 A3
BNL-1681 2007 Sputum Lund, SWE N VIM-2 O12 111 111 A1
OS-210 2007 Urine ICU Stockholm, SWE Y, Tunisia VIM-2 O11 654 E
K44-24 2007 Urine ICU Tønsberg, NOR Y, Thailand IMP-14 O6 260 G
K45-32 2007 Surgical site ICU Oslo, NOR Y, Denmark VIM-2 O12 111 111 A1
a Risk factors according to Hirakata et al. and Zavascki et al. (14, 47), ICU, intensive care unit; UTI, urinary tract infection; ND, neurological disease.
b SWE, Sweden; NOR, Norway.
c Y, yes; N, no.
d MBL allele, serotype, and ST were determined previously (12, 32).
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had previous risk factors associated with infections due to
MBL-producing P. aeruginosa (14, 47), such as intensive care
unit stay, renal failure, neurological disease, or urinary cathe-
ters (Table 1).
Antimicrobial susceptibility profiles. All isolates displayed
an MDR phenotype, with two isolates resistant to all antibiot-
ics tested, including colistin (MIC, 4 g/ml). The carbapenem
MIC was 32 g/ml in all isolates, while the MICs of penicil-
lins and cephalosporins varied but were all in the resistance
range (piperacillin-tazobactam MIC, 32 to 256 g/ml; cefta-
zidime MIC, 64 to 256 g/ml; and cefepime MIC, 32 to 256
g/ml). Five isolates were intermediately susceptible to aztreo-
nam (MIC, 8 to 16 g/ml), while the remaining seven were
resistant (MIC, 32 to 256 g/ml). All isolates were resistant
to tobramycin (MIC, 32 to 256 g/ml) and amikacin (MIC,
32 to 256 g/ml), while six isolates were susceptible (MIC, 2
to 4 g/ml) and seven isolates were resistant (MIC, 8 to 256
g/ml) to gentamicin. Resistance to ciprofloxacin (MIC, 16 to
32 g/ml) was observed in all isolates.
MBL allele and genetic context. Sequencing of the integrons
carrying the MBL genes showed that the six isolates endoge-
nous to Skåne County, AK-5493 (imported from Greece), and
K45-32 (imported from Denmark) all carried blaVIM-2 in In59-
like structures consisting of two aminoglycoside resistance
gene cassettes (aacA29a and aacA29b) and blaVIM-2 (Fig. 1A
and B). The In59-variant in isolates B4-25753, BU-20287, BU-
43038, AK-5493, and BU-36178 were identical to In59.2 from
Greece (GenBank accession no. EU118149) (37), while iso-
lates U9-19005 and BNL-1681 had a 59-base element (59-be)
of aacA29a identical to that of In59.2 but had a 59-be of
aacA29b identical to that of In59 (GenBank accession no.
AF263519) (28) (1 nucleotide difference from the 59-be of
aacA29b in In59.2). The In59 variant in isolate K45-32, on the
other hand, had the same gene cassette (aacA29b) on each side
of the blaVIM-2 gene. In addition, the 59-be of the aacA29b
gene cassette in the first position (normally occupied by
aacA29a) was identical to the 59-base element of aacA29a in
In59.2. In both K34-7 (32) and OS-210, derived from patients
hospitalized in African countries, blaVIM-2 was part of inte-
grons lacking a standard 3 conserved segment (3 CS) consist-
ing of fused qacE1-sul1 genes (Fig. 1C and F). In OS-210,
blaVIM-2 was located in a complex structure as the first gene
cassette of a class 1 integron, followed by the gene cassette
aadB. The 59-be of aadB was followed by another short section
TABLE 2. Primers used to determine the genetic structures surrounding the blaMBL genes in this study and linkage with Tn21
Primer Sequence (533) Target gene/region Reference
5 CS GCC TGT TCG GTT CGT AAG CT intI1 42
3 CS CGG ATG TTG CGA TTA CTT qacE1 42
tniCF CGA TCT CTG CGA AGA ACT CG tniC 42
VIMgen-F2 GTT TGG TCG CAT ATC GCA AC blaVIM 22
VIMgen-R2 AAT GCG CAG CAC CAG GAT AG blaVIM 22
VIMgen-F2Seq GTT CGC ATA TGC GAC CAA AC blaVIM This study
VIMgen-R2Seq CTA TCC TGG TGC TGC GCA TT blaVIM This study
VAR TCA ATC TCC GCG AGA AGT GC blaVIM This study
tnpRF GAT ACA GGG TTT CGC GAC TG tnpR (Tn21) 41
IMPgen-F1 GAA TAG RRT GGC TTA AYT CTC blaIMP 22
IMPgen-R1 CCA AAC YAC TAS GTT ATC blaIMP 22
IMP-X-F AAC ACG GTT TGG TGG TTC TT blaIMP This study
blaPSE-1-F ACC GTA TTG AGC CTG ATT TA blaPSE-1 This study
blaPSE-1-R ATT GAA GCG TGT GTT TGA GC blaPSE-1 This study
PSE-Seq GGA AGC GCT GAT TGC CAT TGT AA blaPSE-1 This study
aadB-F GGC GAG CTC GAG GCA ATA GT aadB This study
aadB-FR AAG CAG GTT CGC AGT CAA GT aadB This study
aadB-RF CTT TCA GGT CGC GAT ATG CG aadB This study
aacA4-Seq1 ACC CGT CGC CGA GCA ACT T aacA4 This study
aacA7-R TTC CGG AAG CAG CGT ACT TG aacA7 41
aacA7-FR TTC AAC AGG CCT GAC GAG CG aacA7 This study
aacA7-RF TGC TCA AGT ACG CTG CTT CC aacA7 This study
arrSeq-1 TAG GTG ACT TGC TTT CGC CT arr-7 This study
arrSeq-2 TAG GAC TTG GTT GGA TTG CC arr-7 This study
aac(6)-lb-F TTG CGA TGC TCT ATG AGT GGC TA aac(6)-Ib/aacA4 25
aac(6)-lb-R CTC GAA TGC CTG GCG TGT TT aac(6)-Ib/aacA4 25
aac(6)-lb-seq CGT CAC TCC ATA CAT TGC AA aac(6)-Ib/aacA4 25
sul1-mF ACG AGA TTG TGC GGT TCT TC sul1 1
sul1-F CGG CGT GGG CTA CCT GAA CG sul1 38
sul1-R GCC GAT CGC GTG AAG TTC CG sul1 38
orf5-F AGG TTG TGC GGC TGA TGC orf5 19
tnpATn5501-pr2 CTT CTC GCT GAC TAT GAG ATC G tnpA (Tn5501) This study
tnpATn5501-pr3 GGA ATA CTT GGC GTT GAC TG tnpA (Tn5501) This study
tnpATn5501-pr4 ATG TCA GCT TCT GCG TGT CCT T tnpA (Tn5501) This study
tnpATn5501-pr5 AAA GCA ATC CTT TGT CGC CGA G tnpA (Tn5501) This study
tnpATn5501-pr6 TCC ACG ATC TAC GCA ACC TGA A tnpA (Tn5501) This study
tnpATn5501-3Seq CCG ATC TGC AAG ATG CAA TA tnpA (Tn5501) This study
strAstrB-F TAT CTG CGA TTG GAC CCT CTG strA 39
strAstrB-R CAT TGC TCA TCA TTT GAT CGG CT strB 39
strAstrB-RF AGC CGA TCA AAT GAT GAG CAA TG strB This study
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of the 5 CS, including a part of the promoter region and a
truncated attI site fused to sul1. No qacE gene was identified.
The original start codon of sul1 was mutated due to the fusion
with the attI site. However, this fusion introduced a putative
start codon for sul1 four codons upstream. The sul1 gene was
followed by a truncated orf5 and two transposons. A Tn5501-
related transposon (34, 35) was inserted into orf5. The inverted
repeat left (IR-L) of Tn5501 in pGNB-1 was also identified on
the left side, while the IR-R was not found in the sequenced
region. On the right side of Tn5501, the sequence data show
insertion of a Tn5393 variant (3). The IR-R of Tn5393 was
identified 4 bp to the right of tnpR of Tn5501, followed by the
streptomycin resistance genes strB and strA and 62 bp of tnpR
of Tn5393.
In two isolates, PA66 (12) and K34-73, blaVIM-4 was identi-
fied in the first position as part of class 1 integrons (Fig. 1D and
E). The aacA4 gene cassette was present in both integrons, but
they carried two different -lactamase genes, blaOXA-35 and
blaPSE-1. The integron in isolate K34-73 also carried a new
putative arr gene (named arr-7), encoding rifampin resistance,
that was most similar to the Arr-4 gene (90% amino acid
identity; GenBank accession number EF660562) (5).
In the only isolate that carried an IMP enzyme (K44-24),
blaIMP-14 was identified in the first position in a class 1 inte-
gron, followed by the aadB gene cassette (Fig. 1G).
In six isolates, blaVIM was linked to Tn21 (data not shown).
The data indicate the same insertion site of the transposon in
four of the isolates with blaVIM-2 as part of an In59-like inte-
gron (U9-19005, AK-5493, B4-25753, and K45-32). In the
other isolates carrying an In59-like integron, blaVIM-2 was not
linked to Tn21. blaVIM-4 in isolates PA66 and K34-73 was also
linked to Tn21, but with different insertion sites.
Location of blaVIM and transferability of resistance. The
blaVIM gene was found to be located on the chromosome in all
isolates by S1 nuclease PFGE and in-gel hybridization (data
not shown). Transfer of the blaVIM genes to P. aeruginosa
PAO1 or E. coli J53-2 was not successful.
Epidemiological typing of isolates by serotyping, PFGE,
and MLST. The typing results are summarized in Table 1. All
isolates from Skåne County (Malmo¨/Lund, Sweden) and
K45-32 (imported to Norway from Denmark) were clonally
related by PFGE (Table 1 and data not shown), were desig-
nated type A1 to A3 (Dice coefficient, 95%), belonged to
ST111, and were of the O12 serotype. AK-5493, previously
typed as ST229, a double-locus variant (DLV) of ST111 and
serotype O12 (12), had a PFGE profile, designated type C,
indicating possible clonal relatedness to ST111 isolates (Dice
coefficient, 76%). MLST showed that RON-2, which also car-
ried In59 (28), displayed ST111 and had a PFGE profile des-
ignated type B (Dice coefficient, 79%). Three isolates were of
the O11 serotype (PA66, K34-73, and OS-210). PA66 had
previously been typed as ST230 (12). K34-73 (PFGE type D1)
showed genetic relatedness to PA66 (PFGE type D; Dice co-
efficient, 86%) and was typed as ST235, a single-locus variant
(SLV) of ST230. The last serotype O11 isolate, OS-210, was
typed as ST654 and was clonally unrelated (PFGE type E) to
the other isolates. Two isolates, K34-7 and K44-24, imported
from Ghana and Thailand, respectively, were of serotype O6
and were clonally unrelated (designated PFGE types F and G,
FIG. 1. Schematic view (not to scale) of the genetic context surrounding the MBL genes in Norwegian and Swedish MBL-producing P.
aeruginosa isolates. (A) Isolates U9-19005, AK-5493, B4-25753, BU-20287, BU-43038, BU-36178, and BNL-1681 (GenBank accession
numbers FN397626, FN397624, FN397621, FN397619, FN397622, FN397620, and FN397625). (B) Isolate K45-32 (GenBank accession
number FN397618). (C) Isolate K34-7 (GenBank accession number FM165436). (D) Isolate PA66 (GenBank accession number AY866525).
(E) Isolate K34-73 (GenBank accession number FN397623). (F) Isolate OS-210 (GenBank accession number FN397628). (G) Isolate K44-24
(GenBank accession number FN397627). The genetic structures of isolate PA66, AK-5493, and K34-7 were determined previously (12, 32).
Open reading frames are represented by arrows indicating the orientation. MBL genes are shown in grey. The 59-be of each gene cassette
is represented by an open circle and the attI site by a gray oval. The partial 5 CS in front of the sul1 gene of OS-210 (F) is represented by
an open rectangle. The inverted repeat of Tn5501 is indicated by a black rectangle, and the inverted repeat of Tn5393 is indicated by a gray
rectangle.
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respectively). K34-7 was typed as ST233 (32) and K44-24 as
ST260.
DISCUSSION
The global dissemination of MBL-producing P. aeruginosa
isolates has reached Scandinavia, a region renowned for its low
level of antibiotic resistance (9, 23, 24). All 13 MBL-producing
P. aeruginosa isolates identified in Norway and Sweden from
1999 to 2007 showed MDR profiles with two isolates resistant
to all antibiotics tested, including colistin.
Seven isolates were derived from patients recently hospital-
ized abroad, suggesting that the import of such strains is sig-
nificant and that human travel contributes to their dissemina-
tion. The different countries (Greece, Ghana, Cyprus, Tunisia,
Thailand, and Denmark) associated with import also under-
score the global dissemination of MBL-producing P. aerugi-
nosa. However, the finding of clonally related, endogenous
isolates in a geographically limited area in Sweden (Skåne
County) over a protracted period of time indicates a back-
ground level and the establishment of MBL-producing P.
aeruginosa with the potential of further dissemination. The
identification of four of these isolates at the same hospital
(Lund) in 2007 indicates local reservoirs and transmissions.
Retrospective analysis of patient histories showed that the
isolates were identified over a 6-month period and that none of
the patients had been admitted to the same department at the
same time. However, possible patient-to-patient, health care
personnel-to-patient, or environment-to-patient transmissions
cannot be ruled out. Interestingly, isolate U9-19005 was iso-
lated in 1999, which makes it the third-earliest VIM-2-positive
P. aeruginosa isolate to be reported.
Two previously described clonal complexes, CC111 (previ-
ously described as CC4/BG4) and CC235 (previously described
as CC11/BG11), have been shown to dominate among MBL-
producing P. aeruginosa isolates (7, 8, 12, 15, 18, 20, 33), and
the same CCs dominate in the isolates from Norway and Swe-
den. All isolates from Skåne County, along with isolates im-
ported from Denmark and Greece, were of serotype O12 and
displayed ST111/ST229, which is part of CC111, and all har-
bored blaVIM-2 as part of In59 variants. In59 was first described
in France in an isolate (RON-2; GenBank accession number
AF263519) from 1998 (28) and has subsequently been identi-
fied in Austria (7), while In59 variants have been identified
in Greece (GenBank accession numbers EU118148 and
EU118149) (37). The differences in the In59 structures in the
isolate from France and isolates from Greece lie in the 59-bes
of the aacA29 gene cassettes (28, 37) and the blaVIM gene
(blaVIM-2/-17). MLST showed that RON-2 also displayed
ST111, and it was possibly related by PFGE. In addition, a
representative strain of the major European O12 clone also
belongs to CC111 (20).
The STs of the two O11 isolates imported from Greece and
Cyprus belonged to CC235, further underscoring the impor-
tance of the CC in the dissemination of MBLs, as it includes
VIM-producing P. aeruginosa of serotype O11 in Europe (8,
12, 18, 20, 33) and IMP- and SPM-1-producing P. aeruginosa
isolates from Japan (15), Brazil, and Singapore (http://pubmlst
.org/paeruginosa).
Both isolates (K34-7 and OS-210) imported from an Af-
rican country harbored blaVIM-2 in unusual integron struc-
tures linked to transposons (Fig. 1C and F). Russian isolates
with the same TniC-like transposon as K34-7 have been typed
as ST235, part of CC235 (33). However, the ST233 of K34-7
(32) could be part of a new CC (CC233) that includes the SLVs
ST742 and ST743 associated with IMP-1-producing P. aerugi-
nosa from Singapore and the DLV ST375 associated with
SPM-producing P. aeruginosa from Brazil (http://pubmlst.org
/paeruginosa). The integron structure of isolate OS-210 was
associated with two transposons, Tn5501 and Tn5393, in which
the TnpA and TnpR protein sequences were identical to TnpA
and TnpR of the Tn5501-related transposon found in the
IncP-1 plasmid pGNB-1 (35). Interestingly, the sequence
downstream of aadB consisted of a partial 5 CS and sul1, as
observed in the In104 region of genomic island SGI1-J found
in Salmonella enterica serovar Emek (19). The mutated start
codon of sul1, along with the putative new start codon, could
result in a Sul1 protein with four additional amino acids at the
N terminus that has previously been inappropriately annotated
as sul3 (27). Whether the sul1 gene is expressed from the new
putative start codon is uncertain. Tn5393 harboring strA-strB
genes found at the end of the integron structure in OS-210 has
also been detected in the genomic island SGI1 of Salmonella
enterica serovar Kentucky (6), and Tn5393 has also been found
to be associated with the extended-spectrum -lactamase
PER-1 in Alcaligenes faecalis (21) and has been identified in
many other bacterial species, both environmental and clinical
(40). OS-210 displayed ST654, which has been shown to be
associated with IMP-type MBL in Singapore (http://pubmlst
.org/paeruginosa/), and the DLV ST741, associated with IMP-1
in Singapore, suggesting a possible new successful CC that is
widespread (http://pubmlst.org/paeruginosa/).
The chromosomal location of blaVIM and the lack of transfer
of blaVIM support the clonal dissemination of MBL-producing
P. aeruginosa. Previous studies have also shown that the ma-
jority of MBL genes are chromosomally located (26).
Interestingly, K44-24 was the only isolate that harbored an
IMP enzyme (IMP-14) and was imported to Norway from
Thailand, the only country where blaIMP-14 had been described
previously (GenBank accession no. AY553332, FJ257650, and
FJ257651). The gene cassette combination of blaIMP-14 and
aadB found in K44-24 was also identical to GenBank accession
no. FJ257651. K44-24 was typed as ST260, an ST in which none
of the associated SLVs and DLVs were associated with
MBL producers (http://pubmlst.org/paeruginosa/), indicating
that MBL-producing isolates with other genetic backgrounds
are circulating.
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